Health
Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia – MD Linx
MDLinx original journal summary on Pneumonia, Infectious Disease from International Journal of Infectious Diseases
In the treatment of severe SARS-CoV-2 pneumonia (SSP), tocilizumab has been used with the aim to relieve the cytokine release syndrome (CRS)-induced acute respiratory distress syndrome (ARDS). Researchers here investigated the patients in whom it might benefit the most. Tocilizumab on a compassionate-use basis was provided to hospitalized patients with SSP (excluding intensive care and intubated cases) who required oxygen support to have a saturation > 93%. They studied a total of 207 patients and…
-
Business19 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Business18 hours ago5 things to watch on the ASX 200 on Monday 7 April 2025
-
Noosa News15 hours agoMeasles alert: Australia Zoo, Hospital ED, Sushi Hub, Holey Moley Mini Golf and train stations among QLD infection sites
-
Business15 hours ago1 ASX dividend stock down 43% I’d buy right now